Head-to-head pivotal clinical trial results showed PONVORY™ treatment led to nearly a third fewer annual relapses than [...]
https://youtu.be/vtwauNrp8Jo Ben Thrower, MD, Medical Director, Andrew C. Carlos Multiple Sclerosis Institute, talks about different [...]
7 5% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease [...]
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
The US FDA has approved inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 [...]
The Plegridy (peginterferon beta-1a) Prescribing Information and the Avonex (interferon beta-1a) Prescribing Information was updated in the [...]
